Program
ASC30
A development code. Also written as “ASC30 tablets A1” and “ASC30 tablets”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by Ascletis Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascletis Pharma | 42 open or running | phase 3since Jul 29, 2026 | Oct 30, 2024 | Jul 2028phase 3 · NCT07743463 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2024First study: phase 1 study in Weight ManagementFirst studyNCT06680440 · 72 enrolled · United States
- Jan 5, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07321678 · 100 enrolled · United States
- Jul 29, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07743463, NCT07743450
Ahead
- Jul 2028Primary completion: phase 3 study in ObesityNCT07743463
- Jul 2028Primary completion: phase 3 study in ObesityNCT07743450
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07743463Obesity · United States, Canada, Czechia and more | 3 | Recruiting | Jul 2028 | 3,003 |
| NCT07743450Obesity · United States, Czechia, Germany and more | 3 | Recruiting | Jul 2028 | 1,560 |
| NCT07321678Diabetes Mellitus, Type 2 · United States | 2 | Completed | Aug 10, 2026 | 100 |
| NCT06680440Weight Management · United States | 1 | Completed | Apr 3, 2025 | 72 |
How it is read
Names in the registry
- “ASC30 tablets A1”, 2 entries
- “ASC30 tablets”, 1 entry
- “ASC30”, 1 entry
Codes read as this program: ASC30.
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.